{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "apixaban",
    "comparative_drug": "dalteparin",
    "study_type": "interventional",
    "interventional_study_phase": "Phase IIIB/Phase 3",
    "study_design": "Prospective Randomized Open Blinded End-point (PROBE), pragmatic, open-label, non-inferiority, active-controlled, event-driven, randomized controlled trial",
    "aim_of_study": "",
    "target_disease": "",
    "type_of_randomization": "randomized controlled trial",
    "randomization_stratification": [],
    "apixaban_dosing": "",
    "dalteparin_dosing": "",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [],
    "primary_efficacy_outcome": "",
    "secondary_efficacy_outcomes": [],
    "primary_safety_outcome": "",
    "secondary_safety_outcomes": [],
    "maximum_sample_size_per_arm": 585,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": []
}